Literature DB >> 33479640

Production of biomedical cell products: requirements for the quality of donor material and excipients of animal origin (review).

Marina A Vodiakova1, Aliya R Sayfutdinova1,2, Ekaterina V Melnikova1, Artem A Goryaev1, Natalia P Sadchikova2, Vladimir I Gegechkori2,3, Vadim A Merkulov1.   

Abstract

Donor biological materials and excipients of animal origin are important components in the production of biomedical cell products (BMCPs). Their quality ensures the stability, safety, effectiveness and purity of the final product. This review discusses quality requirements for biological excipients intended for the production of biomedical cell products, in terms of the necessary information that should be included in the BMCP registration dossier during state registration and is subject to expert assessment during quality control. Considering that there is currently no production of biomedical cell products in the Russian Federation, the authors considered international approaches to ensuring the safety of donor material and excipients for the manufacturing of human cell- and tissue-based products (BMCP analogues). This journal is © The Royal Society of Chemistry 2020.

Entities:  

Year:  2020        PMID: 33479640      PMCID: PMC7580781          DOI: 10.1039/c9md00529c

Source DB:  PubMed          Journal:  RSC Med Chem        ISSN: 2632-8682


  7 in total

Review 1.  Risk of hepatitis and retroviral infections among blood donors and introduction of nucleic acid testing (NAT).

Authors:  R Y Dodd; S L Stramer; J Aberle-Grasse; E Notari
Journal:  Dev Biol (Basel)       Date:  2000

2.  Screening of blood donations by hepatitis C virus polymerase chain reaction (HCV-PCR) improves safety of blood products by window period reduction.

Authors:  W E Hitzler; S Runkel
Journal:  Clin Lab       Date:  2001       Impact factor: 1.138

3.  Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population.

Authors:  R Y Dodd; E P Notari; S L Stramer
Journal:  Transfusion       Date:  2002-08       Impact factor: 3.157

4.  Probability of viremia with HBV, HCV, HIV, and HTLV among tissue donors in the United States.

Authors:  Shimian Zou; Roger Y Dodd; Susan L Stramer; D Michael Strong
Journal:  N Engl J Med       Date:  2004-08-19       Impact factor: 91.245

5.  Eligibility determination for donors of human cells, tissues, and cellular and tissue-based products. Final rule.

Authors: 
Journal:  Fed Regist       Date:  2004-05-25

6.  Risk factors in the development of stem cell therapy.

Authors:  Carla A Herberts; Marcel S G Kwa; Harm P H Hermsen
Journal:  J Transl Med       Date:  2011-03-22       Impact factor: 5.531

Review 7.  Microbiological control in stem cell banks: approaches to standardisation.

Authors:  Fernando Cobo; Glyn N Stacey; Charles Hunt; Carmen Cabrera; Ana Nieto; Rosa Montes; José Luis Cortés; Purificación Catalina; Angela Barnie; Angel Concha
Journal:  Appl Microbiol Biotechnol       Date:  2005-10-26       Impact factor: 4.813

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.